Expands Biocept's intellectual property globally for methods of detecting rare mutations, including cancer biomarkers associated with circulating tumor DNA (ctDNA) SAN DIEGO, April 2, 2020 /PRNewswire ...
A study led by D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare ...
A study led by D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare ...
A retrospective analysis of real-world data showed that <1% of patients with NSCLC had co-mutations in HER2 and EGFR. Median time on treatment with TKIs was longer in patients with concurrent EGFR and ...
The onset and aggressiveness of cancer are related to the abnormal behavior of certain genes, known as oncogenes. The ...
We summarize the evidence regarding the distinct impacts of different HER2 aberrations on antitumor agents. Also, we update the therapeutic efficacy of HER2-targeted agents, including anti-HER2 ...
—These investigators sought to address the lack of clarity surrounding the association between MET genomic alterations and clinical characteristics in lung cancer. Share on Facebook. Opens in a new ...
According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer. Certain features may make patients ...
This patent application has not been assigned to a company or institution. The following quote was obtained by the news editors from the background information supplied by the inventors: “In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results